COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies

Disease modifying therapies and Covid‐19 severity in Multiple Sclerosis

(2021) Maria Pia Sormani et al.   ANNALS OF NEUROLOGY

Effects of disease-modifying therapy on peripheral leukocytes in patients with multiple sclerosis

(2020) F. Schweitzer et al.   JOURNAL OF NEUROLOGY

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

(2020) Roujian Lu et al.   LANCET

Covid-19 — Navigating the Uncharted

(2020) Anthony S. Fauci et al.   NEW ENGLAND JOURNAL OF MEDICINE

Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry

(2020) Milena Gianfrancesco et al.   ANNALS OF THE RHEUMATIC DISEASES

The COVID-19 pandemic and the use of MS disease-modifying therapies

(2020) Gavin Giovannoni et al.   Multiple Sclerosis and Related Disorders

Glatiramer acetate immune modulates B-cell antigen presentation in treatment of MS

(2020) Darius Häusler et al.   Neurology-Neuroimmunology & Neuroinflammation

COVID-19 and MS disease-modifying therapies

(2020) Joseph R. Berger et al.   Neurology-Neuroimmunology & Neuroinflammation

Type 1 interferons as a potential treatment against COVID-19

(2020) Erwan Sallard et al.   ANTIVIRAL RESEARCH

Multiple Sclerosis Disease-Modifying Therapy and the COVID-19 Pandemic: Implications on the Risk of Infection and Future Vaccination

(2020) Crystal Zheng et al.   CNS DRUGS

SARS-CoV-2 infection in patients with autoimmune rheumatic diseases in northeast Italy: A cross-sectional study on 916 patients

(2020) M. Zen et al.   JOURNAL OF AUTOIMMUNITY

Impact of COVID-19 on U.S. and Canadian neurologists’ therapeutic approach to multiple sclerosis: a survey of knowledge, attitudes, and practices

(2020) Farrah J. Mateen et al.   JOURNAL OF NEUROLOGY

An Italian programme for COVID-19 infection in multiple sclerosis

(2020) Maria Pia Sormani   LANCET NEUROLOGY

Dimethyl fumarate treatment shifts the immune environment toward an anti-inflammatory cell profile while maintaining protective humoral immunity

(2020) Erin E Longbrake et al.   Multiple Sclerosis Journal

COVID-19 in multiple sclerosis: The Dutch experience

(2020) Floor C Loonstra et al.   Multiple Sclerosis Journal

Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: The VELOCE study

(2020) Amit Bar-Or et al.   NEUROLOGY

Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis

(2020) Céline Louapre et al.   JAMA Neurology

Leveraging the United States Epicenter to Provide Insights on COVID‐19 in Patients with Systemic Lupus Erythematosus

(2020) Ruth Fernandez‐Ruiz et al.   Arthritis & Rheumatology

B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran

(2020) Farinaz Safavi et al.   Multiple Sclerosis and Related Disorders

COVID-19 in persons with multiple sclerosis treated with ocrelizumab – A pharmacovigilance case series

(2020) Richard Hughes et al.   Multiple Sclerosis and Related Disorders

SARS-CoV-2 infection in immunocompromised patients: humoral versus cell-mediated immunity

(2020) Jia Wei et al.   Journal for ImmunoTherapy of Cancer

COVID-19 outcomes in MS

(2020) Erica Parrotta et al.   Neurology-Neuroimmunology & Neuroinflammation

Risk of COVID-19 infection in MS and neuromyelitis optica spectrum disorders

(2020) Moli Fan et al.   Neurology-Neuroimmunology & Neuroinflammation

COVID-19 Immunopathology and the Central Nervous System: Implication for Multiple Sclerosis and Other Autoimmune Diseases with Associated Demyelination

(2020) Marina Kleopatra Boziki et al.   Brain Sciences

Multiple Sclerosis Disease‐Modifying Therapies in the COVID‐19 Era

(2020) John R. Ciotti et al.   ANNALS OF NEUROLOGY

The potential similarities of COVID-19 and autoimmune disease pathogenesis and therapeutic options: new insights approach

(2020) Sahar Najafi et al.   CLINICAL RHEUMATOLOGY

Variation in racial/ethnic disparities in COVID-19 mortality by age in the United States: A cross-sectional study

(2020) Mary T. Bassett et al.   PLOS MEDICINE

Infections in patients with multiple sclerosis: A national cohort study in Sweden

(2020) Anna Castelo-Branco et al.   Multiple Sclerosis and Related Disorders

Effects of MS disease-modifying therapies on responses to vaccinations: A review.

(2020) John Robert Ciotti et al.   Multiple Sclerosis and Related Disorders

Effect of dimethyl fumarate on lymphocytes in RRMS

(2019) Devangi Mehta et al.   NEUROLOGY

Immunological Aspects of Approved MS Therapeutics

(2019) Paulus S. Rommer et al.   Frontiers in Immunology

Diroximel fumarate (DRF) in patients with relapsing–remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study

(2019) Robert T Naismith et al.   Multiple Sclerosis Journal

Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation

(2018) E. C. Tallantyre et al.   JOURNAL OF NEUROLOGY

Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis

(2018) Alexander Rae-Grant et al.   NEUROLOGY

The Evolving Mechanisms of Action of Glatiramer Acetate

(2018) Thomas Prod'homme et al.   Cold Spring Harbor Perspectives in Medicine

Disease-modifying therapies and infectious risks in multiple sclerosis

(2016) Alexander Winkelmann et al.   Nature Reviews Neurology

Infection risk in systemic lupus erythematosus patients: susceptibility factors and preventive strategies

(2013) A Danza et al.   LUPUS

Effect of rituximab on human in vivo antibody immune responses

(2011) Mark D. Pescovitz et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY